Industry news that matters to you.  Learn more

Archives for April 2014

The Swedish Cancer Institute Launches Personalized Medicine Program

The Swedish Cancer Institute (SCI) recently announced its new Personalized Medicine Program that combines advanced medical treatments based on the unique, molecular signature of a patient’s cancer with supportive care that is designed to serve each individual’s physical and emotional health.

Sanguine to Begin Work with Mayo Clinic Bioservices

Sanguine, a technology company enabling personalized medical research for the development of new and effective treatments, recently announced an agreement with Mayo Clinic Bioservices. Under this agreement, Mayo Clinic Bioservices will process, store and ship biospecimens that Sanguine has collected for clients developing new therapies. This will dramatically increase Sanguine’s capacity and scalability, allowing the company to serve more clients simultaneously.

Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development

Agendia recently announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials.

LifeLabs Medical Laboratory Services and Contextual Genomics Announce Co-Marketing and Testing Agreement

LifeLabs Medical Laboratory Services (“LifeLabs”) and Contextual Genomics recently announced an agreement to co-market and offer tests for cancer and other genetic and genomic tests. This partnership reinforces LifeLabs’ leadership role in genetic testing across Canada and Contextual Genomics’ important role in molecular test development and interpretation. Genetic and genomic testing are the fastest growing segments in laboratory medicine and form the underlying basis for “personalized medicine”. With this partnership LifeLabs and Contextual Genomics have agreed to work together to bring genetic tests for cancer and other genetic-based conditions to physicians and patients across Canada.

More than 7% of the General Population are Affected by Drug Allergy Reactions, Involving Excessive Cost for the Healthcare System

Drug Hypersensitivity Reactions (DHRs) affect 7% of the population[1] and represent a major health problem, as they can be life-threatening and require or prolong hospitalisation[2]. Both underdiagnosis (insufficiently detected) and overdiagnosis (excessive use of the term “allergy”) are common in clinical practice, and can lead to the prescription of more expensive or less effective drugs.